1QFY17 results were in-line with our estimates with Revenues, EBITDA and PAT growing at 3%, 9% and 15% respectively. Inspite of the expanded capacities in anti-protozoals in 4QFY16 sales grew by a palty 3% to INR 292cr as lower crude prices impacted sales / product pricing in Africa and Middle East. Certain LATAM countries witnessed...